Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic cancer cells.
Wei X, Yang J, Adair SJ, Ozturk H, Kuscu C, Lee KY, Kane WJ, O'Hara PE, Liu D, Demirlenk YM, Habieb AH, Yilmaz E, Dutta A, Bauer TW, Adli M.
Wei X, et al. Among authors: lee ky.
Proc Natl Acad Sci U S A. 2020 Nov 10;117(45):28068-28079. doi: 10.1073/pnas.2009899117. Epub 2020 Oct 23.
Proc Natl Acad Sci U S A. 2020.
PMID: 33097661
Free PMC article.